CAS 231277-92-2

Lapatinib

Descrizione:

Lapatinib è un inibitore della tirosina chinasi a piccole molecole utilizzato principalmente nel trattamento di alcuni tipi di cancro al seno, in particolare quelli che sono HER2-positivi. Funziona inibendo l'attività del recettore del fattore di crescita epidermico (EGFR) e HER2, che sono coinvolti nella proliferazione e sopravvivenza delle cellule tumorali. Lapatinib viene tipicamente somministrato per via orale ed è spesso utilizzato in combinazione con altre terapie, come la capecitabina, per aumentarne l'efficacia. Il composto ha una formula molecolare che riflette la sua struttura complessa, che include più anelli aromatici e gruppi funzionali che contribuiscono alla sua attività farmacologica. Lapatinib è caratterizzato dalla sua moderata solubilità nei solventi organici e dalla relativa bassa solubilità in acqua, il che può influenzare la sua biodisponibilità. Gli effetti collaterali possono includere diarrea, eruzione cutanea e potenziali problemi cardiaci, richiedendo un attento monitoraggio durante il trattamento. In generale, Lapatinib rappresenta un approccio terapeutico mirato in oncologia, esemplificando il passaggio verso la medicina personalizzata nel trattamento del cancro.

Formula: C₂₉H₂₆ClFN₄O₄S

InChI: InChI=1/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)

InChI key: InChIKey=BCFGMOOMADDAQU-UHFFFAOYSA-N

SMILES: N(C=1C2=C(C=CC(=C2)C=3OC(CNCCS(C)(=O)=O)=CC3)N=CN1)C4=CC(Cl)=C(OCC5=CC(F)=CC=C5)C=C4

Sinonimi:

• 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-
• 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
• Gd 2016
• Gsk 572016
• Gw 572016
• Gw 572016X
• Lapatinib base
• N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methanesulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
• N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
• N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine
• N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
• N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-Quinazolinamine
• N-[4-(3-Fluorobenzyloxy)-3-chlorophenyl]-6-[5-[[2-(methylsulfonyl)ethylamino]methyl]furan-2-yl]quinazolin-4-amine
• N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine
• Tycerb
• Tyverb
• Lapatinib

Lapatinib

CAS: 231277-92-2

Formula: C₂₉H₂₆ClFN₄O₄S

Purezza: >98.0%(T)(HPLC)

Colore e forma: White to Light yellow powder to crystal

Peso molecolare: 581.06

Ref: 3B-L0360

N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine

CAS: 231277-92-2

Formula: C₂₉H₂₆ClFN₄O₄S

Purezza: 98%

Colore e forma: Solid

Peso molecolare: 581.0575

Ref: IN-DA0039KT

Lapatinib

CAS: 231277-92-2

Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2/10.8 nM) with oral activity.

Formula: C₂₉H₂₆ClFN₄O₄S

Purezza: 99.00% - 99.81%

Colore e forma: Powder

Peso molecolare: 581.06

Ref: TM-T0078

Lapatinib

CAS: 231277-92-2

Formula: C₂₉H₂₆ClFN₄O₄S

Purezza: ≥ 99.0%

Colore e forma: Pale yellow to yellow powder

Peso molecolare: 581.06

Ref: 7W-GP6924

Lapatinib

CAS: 231277-92-2

Lapatinib

Purezza: ≥98%

Peso molecolare: 581.06g/mol

Ref: 54-BUP16996

Lapatinib

CAS: 231277-92-2

Formula: C₂₉H₂₆ClFN₄O₄S

Colore e forma: Yellow Solid

Peso molecolare: 581.06

Ref: 4Z-L-251

Lapatinib

CAS: 231277-92-2

Lapatinib

Purezza: 98%

Peso molecolare: 581.06g/mol

Ref: 54-PC108772

Lapatinib

Prodotto controllato

CAS: 231277-92-2

Applications Lapatinib is a selective inhibitor of epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. This drug is used to treat breast cancer, especially metastatic breast cancer that has progressed after trastuzumab treatment and other chemotherapy.
References Konecny, G., et al.: Cancer Res., 66, 1630 (2006); Geyer, C., et al.: N. Engl. J. Med., 355, 2733 (2006);

Formula: C₂₉H₂₆ClFN₄O₄S

Colore e forma: Light Yellow

Peso molecolare: 581.06

Ref: TR-L175808

Lapatinib

CAS: 231277-92-2

Inhibitor of EGFR (ErbB1) and HER2 (ErbB2) receptor tyrosine kinases. Used for sensitization of HER2-overexpressing cancer cells to radiation as well as chemotherapy to tamoxifen- and trastuzumab-resistant cell lines. The compound blocks signalling via Akt and mitogen-activated protein kinase (MAPK) pathways leading to reduced cell survival. In trastuzumab resistant cancer cells, it inhibits HER2 phosphorylation, prevents receptor ubiquitination and causes accumulation of inactive HER2 dimers on the cell surface.

Formula: C₂₉H₂₆ClFN₄O₄S

Purezza: Min. 95%

Colore e forma: Slightly Yellow Powder

Peso molecolare: 581.06 g/mol

Ref: 3D-FC12433

Lapatinib base - Bio-X ™

CAS: 231277-92-2

Lapatinib is an antineoplastic agent used to treat breast and lung cancer. This drug is also a tyrosine kinase inhibitor and inhibits human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1). Lapatinib has shown to inhibit ERBB-driven tumor cell growth in vitro and in various animal models.

Formula: C₂₉H₂₆ClFN₄O₄S

Purezza: Min. 95%

Colore e forma: Powder

Peso molecolare: 581.06 g/mol

Ref: 3D-BC164610

Lapatinib ditosylate monohydrate

CAS: 231277-92-2

Inhibitor of EGFR (ErbB1) and HER2 (ErbB2) receptor tyrosine kinases. Used for sensitization of HER2-overexpressing cancer cells to radiation as well as chemotherapy to tamoxifen- and trastuzumab-resistant cell lines. The compound blocks signalling via Akt and mitogen-activated protein kinase (MAPK) pathways leading to reduced cell survival. In trastuzumab resistant cancer cells, it inhibits HER2 phosphorylation, prevents receptor ubiquitination and causes accumulation of inactive HER2 dimers on the cell surface.

Formula: C₂₉H₂₆ClFN₄O₄S•(C₇H₈O₃S)₂•H₂O

Purezza: Min. 95%

Peso molecolare: 943.48 g/mol

Ref: 3D-FL24843